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Objectives The aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in pa-
tients with heart failure (HF) with preserved ejection fraction (HFpEF) compared with those with HF with reduced
ejection fraction (HFrEF).
Background There is a paucity of information on the comparative prognostic significance of comorbidities between patients
with HFpEF and those with HFrEF.
Methods In a national ambulatory cohort of veterans with HF, the comorbidity burden of 15 noncardiac comorbidities and
the impacts of these comorbidities on hospitalization and mortality were compared between patients with HFpEF and
those with HFrEF.
Results The cohort consisted of 2,843 patients with HFpEF and 6,599 with HFrEF with 2-year follow-up. Compared with
patients with HFrEF, those with HFpEF were older and had higher prevalence of chronic obstructive pulmonary
disease, diabetes, hypertension, psychiatric disorders, anemia, obesity, peptic ulcer disease, and cancer but a
lower prevalence of chronic kidney disease. Patients with HFpEF had lower HF hospitalization, higher non-HF
hospitalization, and similar overall hospitalization compared with those with HFrEF (p  0.001, p  0.001, and
p  0.19, respectively). An Increasing number of noncardiac comorbidities was associated with a higher risk for
all-cause admissions (p  0.001). Comorbidities had similar impacts on mortality in patients with HFpEF com-
pared with those with HFrEF, except for chronic obstructive pulmonary disease, which was associated with a
higher hazard (1.62 [95% confidence interval: 1.36 to 1.92] vs. 1.23 [95% confidence interval: 1.11 to 1.37],
respectively, p  0.01 for interaction) in patients with HFpEF.
Conclusions There is a higher noncardiac comorbidity burden associated with higher non-HF hospitalizations in patients with
HFpEF compared with those with HFrEF. However, individually, most comorbidities have similar impacts on mor-
tality in both groups. Aggressive management of comorbidities may have an overall greater prognostic im-
pact in HFpEF compared to HFrEF. (J Am Coll Cardiol 2012;59:998–1005) © 2012 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.040Many patients with heart failure (HF) have normal or nearly
normal left ventricular ejection fractions (EFs), a condition
referred to as diastolic HF or HF with preserved EF
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2011, accepted November 15, 2011.(HFpEF). Studies have reported a prevalence of HFpEF
ranging from 30% to 70% (averaging about 50%) among
patients with HF (1–3). Furthermore, the prevalence of
HFpEF among patients with discharge diagnoses of HF has
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increased significantly over the past few decades (4). The
prevalence of this condition is anticipated to keep increasing
as the prevalence of elderly patients with comorbid conditions
such as hypertension, diabetes mellitus (DM), and obesity
increases. Although the morbidity and mortality of patients
with HFpEF in comparison with those with heart failure with
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sus that HFpEF is associated with substantial morbidity and
mortality (3–6).
Previously, the few analyses that examined the causes of death
in patients with HF suggested that a higher proportion of deaths
are due to noncardiovascular causes in patients with HFpEF
compared with those with HFrEF (7–9). This is consistent with
the belief that comorbidities may play a more significant role in
outcomes in HFpEF compared with HFrEF. However, the
relative impacts of comorbidities on morbidity and mortality in
HFpEF compared with HFrEF have not been well studied.
Therefore, in a large, national cohort of ambulatory patients with
HF, we examined the prevalence and relative impacts of a wide
range of noncardiac comorbidities on morbidity and mortality in
patients with HFpEF compared with those with HFrEF.
Methods
Patient cohort and comorbidities. We performed a retro-
spective study of a national cohort of veterans with HF
treated in ambulatory clinics of U.S. Department of Veter-
ans Affairs (VA) medical centers between October 1, 2000,
and September 30, 2002. We used the VA External Peer
Review Program (EPRP) data. As described previously (10),
the sampling pool of outpatients for EPRP included ambu-
latory patients with chronic diseases including HF, DM,
prior myocardial infarction, and chronic obstructive pulmo-
nary disease (COPD), identified by International Classifi-
cation of Disease-Ninth Revision (ICD-9), codes. Abstrac-
tors reviewed electronic medical records for validation of
inclusion criteria, including documentation by clinicians of
the diagnosis of HF and other chronic diseases listed
previously (10). Patient-level data from the EPRP HF
cohort were linked with 5 existing national VA databases to
obtain demographic, comorbidity, laboratory, pharmacy,
and outcome data. The EF and date of its ascertainment
were obtained from the EPRP database. Of patients with
known EFs (n  17,456), only those with EF determina-
tions within 1 year before to 3 months after the clinic visit
(n  9,451) were included in the present analyses. Patients
were classified as having HFpEF when their EFs were
50% and as having HFrEF when their EFs were 50%.
Blood pressure, weight, height, and comorbidities of
prior myocardial infarction, DM, hypertension, and COPD
were obtained from the EPRP database. Other comorbidi-
ties were ascertained using ICD-9 codes from VA outpa-
tient clinic files (containing demographics, diagnoses, and
outpatient services) and patient treatment files (containing
abstracts for patients discharged from VA hospitals) over a
time period of 2 years before and at the index clinic visit
(ICD-9 codes used to identify the comorbidities are listed in
the Online Appendix). On the basis of the Charlson
comorbidity index (11), we included the following noncar-
diac comorbidities: peripheral artery disease, cerebrovascular
accident (CVA), dementia, chronic pulmonary disease,
rheumatological disorders, acquired immunodeficiency syn-drome, peptic ulcer disease, DM,
liver disease, malignancy, and re-
nal disease. Although they are
not included in the Charlson co-
morbidity index, we included
anemia, hypertension, psychiat-
ric disorders, and obesity because
previous studies have identified
them as significant prognostic
variables in patients with HF
(12–14). For each patient, we
calculated the total number of
noncardiac comorbidities from
these 15 comorbidities.
The most recent laboratory
data within 1 year before to 2
weeks after the index visit were
used. Renal insufficiency was de-
fined as an estimated glomerular filtration rate  60
ml/min/1.73 m2, calculated using the 4-variable Modifica-
tion of Diet in Renal Disease formula (15). Anemia was
present if hemoglobin was 13 g/dl in men and 12 g/dl
in women. Obesity was present if body mass index was30
kg/m2. Four patients were excluded because of missing
systolic blood pressure, and 5 patients were excluded be-
cause of missing outcomes. For variables with 20% miss-
ing values, imputation procedures were performed. Vari-
ables with 20% missing values were excluded. Missing
values for serum sodium (6.1%), hemoglobin (15.9%), and
creatinine (11.7%) were imputed. Missing values were
imputed using linear regression with baseline variables as
predictors and constraints applied on the basis of observed
minimal and maximal values. Analyses were repeated by
excluding observations with imputed values, and the results
were found to be concordant. Thus, models using imputed
data are shown.
Statistical analyses. Univariate differences in baseline vari-
ables between HFpEF and HFrEF were evaluated using
chi-square tests for categorical variables and 2-sample t tests
for continuous variables. Covariates for multivariate models
of mortality were selected on the basis of backward stepwise
Cox proportional hazards models with removal set at a
probability of 0.2. On the basis of these results, 19 variables
were selected for the multivariate models. Additionally,
history of hypertension, psychiatric disorder, peptic ulcer
disease and rheumatological disorders were forced into the
model to evaluate the effects of all noncardiac comorbidities
in this population. Multivariate Cox proportional hazards
models were run separately for the HFpEF and HFrEF
groups to calculate the hazard ratios for mortality in each
EF group. Finally, 23 variables were used for the multivar-
iate analyses: age; serum sodium; sex; systolic blood pres-
sure; past hospitalization for HF; use of beta-blockers,
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, and statins; and the 15 comorbidities. In
Abbreviations
and Acronyms
COPD  chronic
obstructive pulmonary
disease
CVA  cerebrovascular
accident
DM  diabetes mellitus
EF  ejection fraction
EPRP  External Peer
Review Program
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
HFrEF  heart failure with
reduced ejection fractionmodels of HFrEF, we also used a categorical variable for the
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erate (30%  EF 40%), and severe (EF 30%). To
evaluate whether the prognostic impact of each comorbidity
was different in the HFpEF versus HFrEF groups, we
performed an interaction analysis. A backward elimination
for the Cox proportional hazards analysis on the entire
dataset was performed to examine the interaction of each of
the 23 variables and the group variable representing HFpEF
or HFrEF. In this analysis, we kept all 23 variables and the
group in the model, allowing the interaction terms to be
removed one by one for p values 0.05.
Kaplan-Meier survival curves were generated, and the
log-rank test was used to compare time to first HF and first
non-HF hospitalization between patients with HFpEF and
those with HFrEF. Follow-up data were available for the
first all-cause admission and HF admission. For survival
analysis of non-HF admissions, only the first all-cause
admission that was not documented as an admission for HF
was considered an event. In addition, occurrence of an
admission for HF was considered a censor for the observa-
Baseline Characteristics of Patients With HFpEFTable 1 Baseline Characteristics of Patient
Variable
HFpE
(n  2,
Age (yrs) 70.7
Men 91.1
Race
Caucasian 78.7
African American 10.1
Other/unknown 11.2
DM 44.9
Hypertension 70.5
Peripheral artery disease 27.5
CVA 21.0
Atrial fibrillation 35.0
Past MI 27.1
Renal insufficiency 48.8
Anemia 33.2
COPD 33.9
Obesity 51.0
Liver disease 1.7
Cancer 21.6
AIDS 0.3
Dementia 3.0
Psychiatric disorders 27.8
Rheumatological disorders 4.4
Peptic ulcer disease 8.1
Systolic blood pressure (mm Hg) 132.2
Serum sodium (mEq/l) 139.1
HF hospitalizations within previous 2 yrs 17.2
Medication use
Beta-blockers 55.7
ACE inhibitors/ARBs 72.8
Statins 45.0
Values are mean  SD or %.
ACE  angiotensin-converting enzyme; AIDS  acquired immunodobstructive pulmonary disease; CVA  cerebrovascular accident; DM  diabe
ejection fraction; HFrEF  heart failure with reduced ejection fraction; MI tion of non-HF admission. All analyses were performed
using SPSS version 18 (SPSS, Inc., Chicago, Illinois). Data
are presented as mean  SD unless otherwise specified, and
p values 0.05 were considered significant.
Results
The cohort consisted of 9,442 veterans with HF, of whom
2,843 (30%) had HFpEF and 6,599 (70%) had HFrEF. All
patients had 2-year follow-up. Patients had a mean age of
70 years, and 95% were men. Of patients with HFrEF, 25%
had mildly reduced EFs, 31% had moderately reduced EFs,
and 44% had severely reduced EFs.
As shown in Table 1, patients with HFpEF were older,
with higher proportions of women and Caucasians. Com-
pared with patients with HFrEF, patients with HFpEF had
higher systolic blood pressure and serum sodium; higher
prevalence rates of DM, hypertension, anemia, COPD,
obesity, cancer, peptic ulcer disease, and psychiatric disor-
ders; but a lower prevalence of past myocardial infarction
Those With HFrEFh HFpEF and Those With HFrEF
HFrEF
(n  6,599) p Value
Age-Adjusted
p Value
69.5 10.3 0.001 NA
96.4 0.001 0.001
0.001 0.001
74.8
13.2
11.9
40.0 0.001 0.001
62.2 0.001 0.001
27.8 0.76 0.42
21.3 0.76 0.48
35.4 0.73 0.22
40.4 0.001 0.001
51.9 0.005 0.001
28.4 0.001 0.001
26.6 0.001 0.001
34.7 0.001 0.001
1.7 1.00 0.81
18.6 0.001 0.01
0.3 1.00 0.84
2.6 0.31 0.56
22.8 0.001 0.001
3.8 0.20 0.22
6.0 0.001 0.001
124.5 20.9 0.001 0.001
139.0 3.5 0.04 0.08
22.9 0.001 0.001
64.9 0.001 0.001
85.5 0.001 0.001
51.3 0.001 0.001
cy syndrome; ARB  angiotensin receptor blocker; COPD  chronicands Wit
F
843)
10.1
21.0
3.4
eficien
tes mellitus; HF  heart failure; HFpEF  heart failure with preserved
myocardial infarction.
S
o
a
c
s
(
a
C
1001JACC Vol. 59, No. 11, 2012 Ather et al.
March 13, 2012:998–1005 Comorbidities in Heart Failureand a mildly lower prevalence of renal insufficiency. In
addition, patients with HFpEF had a lower frequency of
HF hospitalization over the previous 2 years and were less
frequently prescribed beta-blockers, angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, and
statins. Patients with HFpEF had a higher number of
noncardiac comorbidities per patient (mean 4.0  1.7)
compared with patients with HFrEF (mean 3.5 1.7) (p
0.001), ranging from a minimum of 0 to a maximum of 11
comorbidities per patient. There was a significant increase
in the proportion of patients with HFpEF with an increas-
ing number of noncardiac comorbidities (p  0.001 by
trend analysis) (Fig. 1).
We then examined whether the higher prevalence of
comorbidities in patients with HFpEF was associated with
more non-HF hospitalizations compared with patients with
HFrEF. Compared with patients with HFrEF, a higher
proportion of those with HFpEF had at least 1 non-HF-
related admission (p  0.001) but a similar proportion of at
least 1 any-cause admission (p  0.19) and a lower
proportion of at least 1 HF admission (p 0.0001) (Fig. 2).
imilar results were noted in time-to-event analysis, dem-
nstrated by a shorter time to first non-HF admission and
longer time to first HF admission in patients with HFpEF
ompared with those with HFrEF (Fig. 3). There was no
ignificant difference in time to any-cause hospitalization
p  0.60). Next, we examined whether the higher preva-
lence of noncardiac comorbidities in patients with HFpEF
Figure 1
Stacked Bar Chart Showing Relative Composition
of the HF Population (HFpEF vs. HFrEF) Stratified
by the Total Number of Noncardiac Comorbidities
The x-axis represents the total number of prevalent comorbidities, and the
y-axis demonstrates the relative proportion of patients with heart failure (HF)
with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction
(HFrEF) for each category. As the number of prevalent comorbidities increases,
there is a greater proportion of patients with HFpEF compared to patients with
HFrEF (p  0.001 by trend analysis).was a contributor to increased hospitalizations. On multi-
variate survival analysis, number of comorbidities (as a
continuous variable) was significantly associated with time
to all-cause admission (1.19; 95% confidence interval: 1.17
to 1.22; p  0.001). When examined as a categorical
variable, the increasing number of comorbidities also dem-
onstrated an increasing hazard of hospitalization (p 
0.001) (Fig. 4).
During the 2-year follow-up period, there were 1,680
deaths among 6,599 patients with HFrEF (25.5%), whereas
there were 563 deaths among 2,843 with HFpEF (19.8%)
(p  0.001) (Fig. 2). In patients with HFpEF, CVA, renal
insufficiency, anemia, COPD, liver disease, cancer, demen-
tia, rheumatological disorders, and absence of obesity were
independent predictors of all-cause mortality. In patients
with HFrEF, the association of baseline variables with
mortality was found to be similar except for DM and
peripheral artery disease, which were significantly associated
with mortality in addition to previously mentioned comor-
bidities, and history of cancer and rheumatological disor-
ders, which were not (Table 2). However, the interaction
nalyses revealed a significant interaction only between
OPD and EF group (p  0.01). COPD contributed a
higher hazard for mortality in patients with HFpEF
(1.61; 95% confidence interval: 1.36 to 1.92) compared
with those with HFrEF (1.23; 95% confidence interval:
1.11 to 1.37). No other variables had significant interac-
tions with EF group, indicating no significant differences
in the prognostic impact of other comorbidities between
Figure 2
Incidence of Death and at Least 1 All-Cause
Admission, HF Admission, and Non–HF-Related
Admission in Patients With HFpEF and Those With HFrEF
The medians (interquartile ranges) follow-up for these end-points were 730
days (730 to 730 days), 518 days (138 to 730 days), 730 days (474 to 730
days), and 518 days (138 to 730 days), respectively. HF  heart failure;
HFpEF  heart failure with preserved ejection fraction; HFrEF  heart failure
with reduced ejection fraction. *p  0.001.the 2 EF groups.
1002 Ather et al. JACC Vol. 59, No. 11, 2012
Comorbidities in Heart Failure March 13, 2012:998–1005Discussion
In a large national ambulatory HF cohort, we demonstrate
that patients with HFpEF have a significantly higher
burden of noncardiac comorbidities compared with those
with HFrEF. Patients with HFpEF experienced signifi-
cantly more non-HF hospitalizations compared with those
with HFrEF, although overall hospitalizations were similar
in both groups. The increasing number of comorbidities was
associated with an increase in all-cause hospitalizations.
Furthermore, individually, most of the noncardiac comor-
Figure 3 Kaplan-Meier Curves for Hospitalization in Patients W
(A) Heart failure (HF) admissions and (B) non-HF admissions. Hazard ratios (HRs)
HFpEF  heart failure with preserved ejection fraction; HFrEF  heart failure with r
Figure 4 Risk for All-Cause Hospitalization
Versus Number of Noncardiac Comorbidities
Log hazard ratios are based on Cox proportional hazards model (p  0.001).
Number of noncardiac comorbidities was used as a categorical variable. Error
bars represent the upper limit of the 95% confidence interval.bidities had similar prognostic impacts on mortality in
HFpEF and HFrEF.
Our study adds to previous studies by demonstrating a
higher burden of noncardiac comorbidities in ambulatory
patients with HFpEF compared with those with HFrEF.
Most of the large published studies evaluating comorbidities
in patients with HFpEF were based on hospitalized HF
cohorts (1,2,4). In contrast, our study evaluated a large
nationally representative cohort of 9,442 ambulatory pa-
FpEF and Those With HFrEF
were calculated using univariate Cox proportional hazards models.
d ejection fraction.
Hazard Ratios (95% Confidence Intervals)of Noncard ac Comorbidities for Mortality inP tie ts W th HFpEF a d Thos With HFrEF
Table 2
Hazard R tios (95% C nfidence Intervals)
of Noncardiac Comorbidities for Mortality in
Patients With HFpEF and Those With HFrEF
Variable HFpEF HFrEF
p Value for
Interaction
Analyses
DM 1.03 (0.86–1.24) 1.25‡ (1.13–1.38) 0.20
Hypertension 1.03 (0.85–1.24) 1.03 (0.93–1.15) 0.66
Peripheral artery disease 1.17 (0.97–1.40) 1.38‡ (1.25–1.53) 0.11
CVA 1.25* (1.02–1.52) 1.18† (1.05–1.32) 0.53
Renal insufficiency 1.28† (1.07–1.53) 1.25‡ (1.12–1.38) 0.86
Anemia 1.35† (1.13–1.61) 1.42‡ (1.28–1.57) 0.84
COPD 1.61‡ (1.36–1.91) 1.23‡ (1.11–1.37) 0.01
Obesity 0.67‡ (0.56–0.81) 0.83† (0.74–0.93) 0.09
Liver disease 2.31‡ (1.48–3.62) 1.41* (1.05–1.89) 0.06
Cancer 1.24* (1.03–1.49) 1.10 (0.98–1.24) 0.33
AIDS 2.38 (0.76–7.48) 1.52 (0.72–3.22) 0.53
Dementia 1.75† (1.21–2.51) 1.48† (1.16–1.90) 0.70
Psychiatric disorder 1.05 (0.87–1.27) 1.02 (0.91–1.15) 0.57
Rheumatological disorder 1.52* (1.06–2.17) 0.96 (0.75–1.23) 0.054
Peptic ulcer disease 0.81 (0.60–1.10) 1.07 (0.89–1.29) 0.21
Other baseline covariates used in the model were age, sex, systolic blood pressure, serum sodium,
past heart failure hospitalization, and use of beta-blockers, angiotensin-converting enzyme inhib-
itors or angiotensin receptor blockers, and statins. In the HFrEF group, reduced ejection fraction
was used in the model as a categorical variable of mildly, moderately, or severely reduced ejectionith H
shown
educefraction. *p  0.05; †p  0.01; ‡p  0.001.
Abbreviations as in Table 1.
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sentative of the overall HF population rather than the
sickest subgroup of hospitalized patients. In addition, most
of the previous investigations examined only a limited
number of comorbidities in each study, and the specific
comorbidities assessed varied across studies. In the present
study, we included a comprehensive set of noncardiac
comorbidities. Our study confirmed findings from previous
studies demonstrating that patients with HFpEF are typi-
cally older and have comorbidities including hypertension
(55% to 86%), DM (26% to 45%), CVA (15% to 17%),
obesity (41% to 62%), COPD (7% to 31%), and anemia
(21% to 53%), which were usually more prevalent than in
patients with HFrEF (1–4,6,16). Although the prevalence
of DM has varied across studies, the majority of studies have
found a higher prevalence of DM in patients with HFpEF,
consistent with the findings in our study. In the
OPTIMIZE-HF (Organized Program to Initiate Lifesav-
ing Treatment in Hospitalized Patients With Heart Failure)
registry, lower serum creatinine was noted in patients with
HFpEF compared with those with HFrEF, while other
studies demonstrated no significant difference in serum
creatinine between the 2 groups (1,2,6). In our cohort,
patients with HFpEF had a slightly lower prevalence of
renal insufficiency in comparison with those with HFrEF.
For our analysis, renal insufficiency was defined by estimated
glomerular filtration rate, which may be a more accurate
measure of renal function than serum creatinine.
Although overall hospitalizations were similar between
HFpEF and HFrEF, non-HF hospitalizations were signif-
icantly higher in the HFPEF group. These findings are
supported by a previous study of 1,077 patients with HF
from Olmstead County, Minnesota, which suggested a
higher frequency of admissions for patients with HFpEF
compared with those with HFrEF (40% vs. 34%, respec-
tively) although in that study, the difference was not
statistically significant (p  0.069) (17). These findings are
consistent with the greater burden of noncardiac comorbidi-
ties we found in patients with HFpEF and underline the
importance of comorbidity management in reducing the
overall morbidity in patients with HFpEF. Focusing pre-
dominantly on the reduction of HF admissions in these
patients may result in a lower impact on their overall
frequency of hospitalization. This has also been evident in
recent large trials of in HFpEF targeting the renin-
angiotensin system, some of which showed modest reduc-
tions in HF hospitalizations (18,19) but failed to reduce
all-cause mortality and/or non-HF hospitalizations (18–20). In
the I-PRESERVE (Irbesartan in Heart Failure With Pre-
served Ejection Fraction) trial, more than 50% of patient
hospitalizations were for noncardiovascular causes. This
higher rate of noncardiovascular hospitalization occurred
despite the trial’s having multiple exclusion criteria for
significant comorbidities (20). Patients in clinical practice,
such as our study cohort, would be expected to have an even
greater contribution of comorbidities to outcomes. Thus, itis possible that HF-specific treatment in patients with
HFpEF may not be able to reduce total hospitalization or
total mortality that is largely driven by competing noncar-
diac comorbidities.
The greater burden of comorbidities in HFpEF is also
consistent with the prior finding of a higher proportion of
noncardiovascular deaths in patients with HFpEF com-
pared with those with HFrEF (7–9). However, on exami-
nation of the relative prognostic impacts of individual
comorbidities on mortality in the HFpEF and HFrEF
groups, we found that most comorbidities, including renal
disease, anemia, prior CVA, liver disease, cancer, dementia,
and obesity, had similar prognostic impacts on mortality in
the 2 EF groups. Although these comorbidities have been
shown, in various combinations, to be associated with
intermediate-term or long-term mortality in HFpEF or in
HFrEF (4,6,21), most previous studies did not examine the
differential prognostic impacts of a comprehensive set of
noncardiac comorbidities in both these EF groups. We
found that only COPD was associated with a significantly
higher hazard of death in patients with HFpEF compared
with those with HFrEF, although COPD was an indepen-
dent predictor of mortality in both groups. Although
previous studies have found a higher prevalence of COPD
in patients with HFpEF compared with those with HFrEF
(2,6) and have demonstrated that COPD is associated with
higher mortality in patients with HF, few studies have
addressed its comparative prognostic role in preserved-EF
and reduced-EF groups (21,22). One small study of 528
hospitalized patients with HF demonstrated results similar
to ours in that the investigators found an increased risk for
death associated with COPD in patients with HFpEF
compared with those with HFrEF (23). The complex
relationship between COPD and HF, including overlap-
ping symptoms, contributes to difficulties in making the
diagnosis of one in the presence of the other, and the role of
each of the conditions in the progression and exacerbation
of the other requires further study (22).
On the basis of our findings, a greater focus on the
recognition and treatment of comorbidities in HFpEF
appears warranted. Patients with HFpEF, who are often
older and have multiple chronic health conditions with
complex health care needs, may benefit from newer models
of primary care to improve the fragmented and often
ineffective care that such patients may receive in the current
health care system (24). In addition, studies have also shown
that although the clinical signs and symptoms of HF are
similar between HFpEF and HFrEF, patients with HFpEF
are less likely to receive diuretic agents for congestion,
anticoagulation therapy for atrial fibrillation, smoking ces-
sation counseling, complete discharge instructions, to have a
cardiologist as a primary physician, or to undergo consulta-
tion with a cardiologist (1,6). Attempts to pursue case
management strategies for patients with HFpEF, as done
for those with HFrEF, may help reduce the morbidity
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strategies may be warranted to treat comorbidities. For
example, as demonstrated by large randomized clinical
trials, 1 of the most beneficial effects of better blood pressure
control is the reduction of HF events (25,26). Smaller
studies demonstrating benefits of treatment of anemia and
sleep-disoreded breathing in patients with HFpEF need
further evaluation in larger clinical trials (27,28). To in-
crease the applicability of clinical trial results to the general
population, our findings support changes in clinical trial
strategy, as suggested recently by Kitzman and Rich (29).
These include efforts to enroll a greater proportion of elderly
patients in trials of HFpEF, to discourage the exclusion of
patients with multiple comorbidities as they are the driving
force of outcomes in HFpEF, and to include the primary
evaluation of outcomes of functional ability rather than just
mortality and HF hospitalizations.
Study limitations. This study had limitations inherent to
retrospective observational studies. Also, our database had
missing data for some variables, ranging from 6% to 16%.
This had the potential to bias the study if the missing data
were not completely random. To address this issue, we
conducted the analyses both with imputed data and by
excluding patients with missing data and found concor-
dant results. In addition, the study cohort was predom-
inantly male (91%), representative of the VA population,
and the results may not be generalizable to women, who
form a large proportion of patients with HFpEF. The
male dominance may also explain the lower prevalence of
HFpEF (30%) in our study cohort compared to other
U.S. databases. Furthermore, patients were initially iden-
tified by ICD-9 codes for HF. Thereafter, the data
abstractors for EPRP confirmed physician documenta-
tion of HF in the electronic medical records. Relying on
physician diagnosis of HF lends itself to the possibility of
some misclassification, especially in patients with HF-
pEF, in whom coexistent obesity and/or COPD may
confound the diagnosis of HF.
Conclusions
Although there is a higher prevalence of noncardiac
comorbidities in patients with HFpEF compared with
those with HFrEF, most individual comorbidities have
comparable prognostic impact on mortality in both EF
groups. The higher overall burden of comorbidities in
HFpEF is associated with higher non-HF morbidity in
patients with HFpEF compared with those with HFrEF.
This underlines the importance of therapeutic approaches
with greater emphasis on management of comorbidities
in patients with HFpEF. Treatment strategies aimed
mainly at reducing HF morbidity and mortality may have
less overall impact on morbidity and mortality in patients
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APPENDIX
For a list of ICD-9 codes used to identify comorbidities,
please see the online version of this article.
